Novem Group Takes Position in Pfizer Inc. (NYSE:PFE)

Novem Group acquired a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 14,266 shares of the biopharmaceutical company's stock, valued at approximately $378,000.

Several other institutional investors and hedge funds have also recently modified their holdings of PFE. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer during the 4th quarter worth approximately $26,000. Clarity Asset Management Inc. purchased a new position in shares of Pfizer in the 4th quarter worth $27,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer in the 4th quarter worth $28,000. Noble Wealth Management PBC purchased a new position in shares of Pfizer in the 4th quarter worth $31,000. Finally, Bernard Wealth Management Corp. purchased a new position in Pfizer in the fourth quarter worth about $33,000. Institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

PFE opened at $23.02 on Friday. The business has a fifty day moving average of $23.44 and a 200 day moving average of $25.22. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market cap of $130.88 billion, a P/E ratio of 16.33, a PEG ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same period last year, the company posted $0.82 earnings per share. The company's quarterly revenue was down 7.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.47%. Pfizer's dividend payout ratio is currently 124.64%.

Analyst Upgrades and Downgrades

Several research analysts recently commented on PFE shares. Cantor Fitzgerald initiated coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target for the company. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. UBS Group upped their price objective on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Finally, The Goldman Sachs Group reaffirmed a "neutral" rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.